TSThomas Schmidt

Thomas Schmidt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Schmidt has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • A. Linke

    Department for Internal Medicine and Cardiology, Heart Center Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany

    1 shared publication
  • Ali El-Armouche

    Department of Pharmacology and Toxicology, TU Dresden, Fetscherstrasse 76, 01307 Dresden, Germany

    1 shared publication
  • Anastasia Hankel

    Steinbeis Research Institute ‘Rhythm and Heart’, Pfotenhauer Straße 76, 01307 Dresden, Germany

    1 shared publication
  • Angela Zedda

    Department of Electrophysiology, Heart Center Dresden, Dresden University of Technology, Dresden, Germany (Y.H., A.Z., S.U., J.M., L.P., U.R., T.G., J.P., C.P.)

    1 shared publication
  • Bettina Kirstein

    Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany

    1 shared publication
  • Christopher Piorkowski

    Department of Electrophysiology, University of Leipzig, Heart Center, Leipzig, Germany

    1 shared publication

Latest Publications

  • Open Access

    Left atrial epicardial adipose tissue volume quantification by CMR aids identification of patients at low risk for left atrial cardiomyopathy

    by T. R. Schmidt, S. Ulbrich, T. Gaspar, M. Wagner, S. Richter, A. Linke, F. M. Heidrich

    Background and aims: The pathophysiologic concept of atrial fibrillation (AF) has evolved towards defining atrial cardiomyopathy, recognizing inflammation-mediated remodeling of the left atrium (LA) as a source for arrhythmogenesis. One feature of atrial cardiomyopathy is the development of fibrosis, with low-voltage zones (LVZ) identified by invasive electroanatomic mapping as an accepted surrogate parameter. A mediator of pathological remodeling is epicardial adipose tissue (EAT). This study sought to explore LA-EAT volume, as a predictor of LVZ in patients presenting for primary AF ablation. Methods and results: CMR imaging of left atrial epicardial adipose tissue was performed using fat–water separation Dixon-based sequences in 58 patients (mean age 68.2 ± 10.1 years) presenting for primary pulmonary vein isolation (PVI). Additionally, left atrial volume index (LAVi) was derived from contrast-enhanced angiography. Left atrial epicardial volume index (LA-EATVi) was a significant predictor of LVZ, with significantly higher volumes in LVZ + patients (mean difference of 7.2 ± 2.4 ml/m 2 ), a moderate correlation ( r = 0.37, p < 0.001), and a univariate predictive ability with an area under the curve (AUC) of 0.71. Expanding the prediction model with age, gender, and LAVi improves the prediction of LVZ up to an AUC of 0.91. Cutoff selection at 0.25 predicted probability identifies a low-risk group for LVZ, with a negative predictive value of 96.7%, sensitivity 95%, and specificity 76.3%. Conclusion: The pre-procedural identification of a low risk of atrial cardiomyopathy is important to select patients for single-shot catheter ablation. LA-EATVi proved to be of additive value to known risk factors for the prediction of LVZ in a combined prediction model. Patients not considered low risk could be offered an electroanatomic atrial mapping for LVZ detection with the possibility of an LVZ-based radiofrequency ablation approach. Individualized matching of patient and ablation technique using an LVZ prediction model might lead to improved ablation outcomes. Graphical


  • Left atrial fibrosis predicts left ventricular ejection fraction response after atrial fibrillation ablation in heart failure patients: the Fibrosis-HF Study

    by Bettina Kirstein, Sebastian Neudeck, Thomas Gaspar, Judith Piorkowski, Simon Wechselberger, Mads Brix Kronborg, Angela Zedda, Anastasia Hankel, Ali El-Armouche, Jakub Tomala, et al.

    Aims: Atrial fibrillation (AF) and heart failure (HF) often coexist. Catheter ablation has been reported to restore left ventricular (LV) function but patients benefit differently. This study investigated the correlation between left atrial (LA) fibrosis extent and LV ejection fraction (LVEF) recovery after AF ablation. Methods and results: In this study, 103 patients [64 years, 69% men, 79% persistent AF, LVEF 33% interquartile range (IQR) (25–38)] undergoing first time AF ablation were investigated. Identification of LA fibrosis and selection of ablation strategy were based on sinus rhythm voltage mapping. Continuous rhythm monitoring was used to assess ablation success. Improvement in post-ablation LVEF was measured as primary study endpoint. An absolute increase in post-ablation LVEF ≥10% was defined as ‘Super Response’. Left atrial fibrosis was present in 38% of patients. After ablation LVEF increased by absolute 15% (IQR 6–25) (P < 0.001). Left ventricular ejection fraction improvement was higher in patients without LA fibrosis [15% (IQR 10–25) vs. 10% (IQR 0–20), P < 0.001]. An inverse correlation between LVEF improvement and the extent of LA fibrosis was found (R2 = 0.931). In multivariate analysis, the presence of LA fibrosis was the only independent predictor for failing LVEF improvement [odds ratio 7.2 (95% confidence interval 2.2–23.4), P < 0.001]. Echocardiographic ‘Super Response’ was observed in 55/64 (86%) patients without and 21/39 (54%) patients with LA fibrosis, respectively (P < 0.001). Conclusion: Presence and extent of LA fibrosis predict LVEF response in HF patients undergoing AF ablation. The assessment of LA fibrosis may impact prognostic stratification and clinical management in HF patients with AF.